The number of new drugs being marketed has reached new heights, the scale of clinical trials has steadily ranked among the highest in the world, and cross-border cooperation on pharmaceutical licensing has continued to deepen. Recently, China's pharmaceutical innovation has received widespread attention from foreign media. Many foreign media reported that China is continuously exporting cost-effective high-quality diagnostic and treatment solutions with its vigorous innovation, efficient R & D system and broad space for cooperation, becoming an important source of global pharmaceutical innovation.
Vibrant Innovation:
In 2025, 76 new drugs were approved for marketing in China, and the total number of new drugs in development reached 4,751, becoming the largest country in the world for the first time.
Intravascular ultrasound diagnostic equipment is like a "micro camera" put into a blood vessel, providing a new option for ultrasound imaging. The new innovative weight loss drug represented by Enoglutide Injection has fewer gastrointestinal side effects; The world's first CAR-T cell therapy approved for the treatment of solid tumors, fights stomach cancer by modifying a patient's own immune cells... Chinese pharmaceutical innovation is continually providing new solutions for clinical treatment.
A total of 76 innovative drugs and 76 innovative medical devices were approved for listing in China in 2025, setting a record high, according to data released by the National Medical Products Administration. By the end of 2025, the total number of new drugs under development in China reached 4,751, accounting for 33.7% of the global total, making it the largest country in the world.
As the scale of pharmaceutical innovation continues to expand, many foreign media have published articles focusing on the development of innovative drugs in China.
"China currently occupies a technological leadership position in areas such as anti-cancer drugs and weight loss drugs, and maintains a research and development speed and cost-effectiveness that exceeds the industry average," according to a report in the American professional industry media "Drug Discovery and Development." France's Le Monde newspaper recently reported that China is surpassing Europe as an important source of new drugs in the world and gradually narrowing the gap with the United States in medical innovation.
From producer to innovator, China's role in healthcare innovation is changing.
The Wall Street Journal wrote that the world's largest pharmaceutical companies are turning to China for innovation inspiration.“Once, Chinese companies could only produce pharmaceutical raw materials or low-cost generic drugs, but now China has become a major player in biotechnology. Large pharmaceutical companies and investors looking to take advantage of China's innovative capabilities are turning their attention to Chinese original drugs.”
According to global industry data service provider GlobalData, the number of new clinical trials launched globally in the first quarter of 2026 increased by 1.3% compared to the same period in 2025, and the number of China's new clinical studies increased by 6.5% year-on-year, accounting for one-third of the global total. The Washington Observer commented that more and more Phase I and Phase II bedside trials are accelerating to transfer to China, and China is winning the 'first mile' of drug innovation.

More Efficient R & D:

The time taken by Chinese pharmaceutical companies to move from the drug discovery stage to the launch of human clinical trials is about half the global average.

Where does innovation in Chinese medicine come from? Several foreign media gave their observations and interpretations from different perspectives.
The steady development benefits from long-term planning.
Stefan Erlich, a board member and head of the pharmaceutical division of Bayer AG, said in an interview that the rise of biopharmaceutical innovation in China is largely due to the long-term strategic layout of the biotechnology sector. He pointed out that the 15th Five-Year Plan explicitly proposed the implementation of the health-first development strategy and listed biopharmaceutical as an emerging pillar industry, and China is turning the blueprint into reality with determined steps.
Higher R & D capacity stems from an increasingly improved innovation ecosystem.
The Wall Street Journal pointed out that the Chinese government has funded the construction of scientific research laboratories and set up special units for the training of doctoral candidates at the same time. At the same time, the state has introduced complementary regulatory mechanisms to shorten the clinical trial and approval cycle of candidate drugs, and significantly reduce the R & D threshold for drug innovation for researchers. The New York Times also reported that China has invested heavily in biotechnology research, continuously improved its R & D infrastructure, and focused on cultivating a pool of young research talent. "China's talent pool in life sciences is rapidly expanding, laying a solid foundation for achieving innovative breakthroughs."
In addition to the jump in R & D capabilities, the advantages of Chinese pharmaceutical innovation in terms of cost and efficiency have also received widespread attention.
French newspaper Libération published an article saying that with a sound production system, a complete industrial chain and significant economies of scale, the price of Chinese innovative drugs after their market debut is often much lower than that of similar products in Europe and the United States."Some cancer treatment options can save tens of thousands of euros per patient per year when they enter the French healthcare system." The Economist's website has also published an article focusing on the efficiency of China's innovative drug research and development: Chinese drug companies move drugs from the discovery stage to the launch stage of human clinical trials in about half the time of the global average. The large patient population reduces the organizational difficulty of clinical trials, and the widely distributed network of clinical research centers greatly accelerates the research process.
At the same time, the integration of artificial intelligence technology is becoming an important trend in the field of biotechnology. The South China Morning Post has focused on the use of smart technology in new drug development - Chinese scientists are using supercomputers to quickly screen hundreds of millions of molecules for potential candidate compounds that bind to disease targets, reducing a screening cycle that would have taken years to a few seconds. Nikkei Asia also points to the same trend: "Companies are no longer limited to developing a few drug candidates, but are focusing on building drug discovery platform technology and deeply integrating artificial intelligence technology for R & D."
The U.S. financial website Seeking Alpha concluded that China's strength in healthcare and drug research and development reflects a large amount, The organic combination of cost efficiency, technological strength and other factors,“Together, these factors will create a faster-iterative R & D model that is deeply integrated into global value chains. China is no longer just a low-cost manufacturing hub, it is growing into a powerful engine of global healthcare innovation.”

Wide Room for Cooperation:
Chinese pharmaceutical innovation attracts more international cooperation and accelerates the birth of new drugs with better value for money
As Chinese innovative medicines enter the global landscape, more and more international cooperation is driving global enterprises to form synergies and jointly expand the technological frontier.
Recently, a number of landmark deals have attracted the attention of foreign media. In May, Pfizer and Cinda Biotech signed a global strategic licensing and joint development agreement worth 10.5 billion U.S. dollars. The two sides will jointly develop 12 early-stage cancer drugs; At almost the same time, Bristol-Myers Squibb and Jiangsu Hengrui Pharmaceutical reached a global strategic cooperation with a potential total transaction value of more than 15 billion US dollars.
The United States "Wired China" magazine issued an article saying that only in the first two months of 2026, the total amount of foreign authorization transactions signed by Chinese enterprises and multinational companies exceeded 50 billion U.S. dollars, hitting a new high in the past five years. Reuters quoted analysts as saying that the cost of importing Chinese biotechnology patents is much lower than the cost of independent research and development, and the industry expects the volume of outbound Chinese biotechnology licensing deals to hit a record high in 2026.
Many foreign media have noticed that in China, biomedical innovation is far more than commercial benign competition, it is an important force to promote medical progress and allow more patients around the world to have access to cheaper and better-performing drugs.
The British Economist pointed out the win-win mechanism in international pharmaceutical cooperation - multinational pharmaceutical companies are adept at promoting the late clinical, regulatory approval and global commercialization of candidates. Chinese companies have outstanding advantages in early-stage target research and development and low-cost rapid clinical trials, and the two sides are highly complementary. "No matter where new drugs come from, patients around the world can benefit from faster and more affordable treatment options."
David Law, head of healthcare investment banking for Asia Pacific at JPMorgan, was quoted by Bloomberg as saying that cross-border cooperation fostered by Chinese pharmaceutical innovation can be mutually beneficial: local pharmaceutical companies receive adequate R & D funding, Overseas giants rapidly expand their innovation pipelines, and eventually both Chinese and foreign patients can use high-cost innovative drugs earlier. The New York Times has also pointed out in its analysis of biotechnology developments in China and the United States that expanding the supply of innovative drugs in China would both enrich treatment options for patients worldwide and help reduce drug prices. "Working together to make people live longer and healthier lives."
Stefan Erlich said in the interview that the ultimate goal of healthcare innovation, wherever it is, is to benefit everyone. Inventing new things and discovering new mechanisms by which diseases work are not specifically for people in one country - "it's usually something we're trying to give to the whole world." (Outlook New Era)